I'm LongbridgeAI, I can summarize articles.Alps Group reported a narrowed net loss of USD 2.09 million for FY26, down from USD 2.62 million previously. Revenue surged 44% to USD 4.86 million, driven by strong growth in cellular therapy and medical services. However, gross margin declined due to a shift toward aesthetic services. Administrative expenses rose significantly, including non-recurring De-SPAC fees related to its Nasdaq listing.
- Alps Group posted a net loss of USD 2.09 million, narrowing from USD 2.62 million a year earlier. * Revenue rose 44% to USD 4.86 million, led by 51% growth in cellular therapy sales and a 20% increase in medical testing and aesthetics services. * Gross margin fell 6.5 percentage points to 32.1%, reflecting a shift toward aesthetic services with profit-sharing recorded in cost of sales. * Other operating income climbed to USD 1.33 million, driven by a USD 583,084 loan-modification gain and a USD 477,972 warrant-liability fair value gain. * Administrative expenses increased to USD 3.5 million, including USD 1.16 million of non-recurring De-SPAC professional fees tied to the Nasdaq listing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alps Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036364), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here